JAMES J. MARINO - Corporate Board Profile

Celldex Therapeutics, Inc.

Filing Date	Source Excerpt
2017-04-28	James J. Marino became a director of Celldex in March 2017. The Board of Directors has established a Compensation Committee currently consisting of James J. Marino, Chair, Herbert J. Conrad and Harry H. Penner, Jr.
2018-04-30	James J. Marino Age 68 Year First Became Director 2017 The Board of Directors has established a Compensation Committee currently consisting of James J. Marino, Chair, Herbert J. Conrad and Harry H. Penner, Jr. The following table summarizes the annual compensation for our non-employee directors during 2017. James J. Marino Fees Earned or Paid in Cash $70,000 Stock Awards $23,200 Option Awards $42,538 Total $135,738
2019-04-26	James J. Marino became a director of Celldex in March 2017. He is Chair of the Compensation Committee. Compensation for 2018 was $90,469.
2020-04-28	James J. Marino became a director of Celldex in March 2017. The Board of Directors has established an Audit Committee currently consisting of Keith L. Brownlie, Chair, James J. Marino and Harry H. Penner, Jr. The Board of Directors has established a Compensation Committee currently consisting of James J. Marino, Chair, Herbert J. Conrad and Harry H. Penner, Jr. The following table summarizes the annual compensation for our non-employee directors during 2019. James J. Marino received $57,758 in fees and $9,386 in option awards, totaling $67,144.
2021-04-27	James J. Marino became a director of Celldex in March 2017. Mr. Marino has served as a member of the board of directors of Onconova Therapeutics, Inc., a publicly held biopharmaceutical company, since July 2015 and currently serves as Chairman of the Board. ... The Board of Directors has established an Audit Committee currently consisting of Keith L. Brownlie, Chair, James J. Marino and Harry H. Penner, Jr. ... The Board of Directors has established a Compensation Committee currently consisting of James J. Marino, Chair, Herbert J. Conrad and Harry H. Penner, Jr. ... The following table summarizes the annual compensation for our non-employee directors during 2020. James J. Marino Fees Earned or Paid in Cash $60,000 Option Awards $87,586 Total $147,586.
2022-04-26	James J. Marino became a director of Celldex in March 2017. ... The Board of Directors has established an Audit Committee currently consisting of Keith L. Brownlie, Chair, James J. Marino and Harry H. Penner, Jr. ... The Board of Directors has established a Compensation Committee currently consisting of James J. Marino, Chair, Herbert J. Conrad and Harry H. Penner, Jr. ... The following table summarizes the annual compensation for our non-employee directors during 2021. ... James J. Marino Fees Earned or Paid in Cash ($) 60,000 Option Awards ($) 260,828 Total ($) 320,828.
2023-04-25	James J. Marino 73 2017 2 The Board of Directors has established an Audit Committee currently consisting of Keith L. Brownlie, Chair, James J. Marino and Harry H. Penner, Jr. The Board of Directors has established a Compensation and Organization Development Committee currently consisting of James J. Marino, Chair, Cheryl L. Cohen and Harry H. Penner, Jr. The following table summarizes the annual compensation for our non-employee directors during 2022. James J. Marino Fees Earned or Paid in Cash ($) 65,816 Option Awards ($) 231,866 Total ($) 297,682
2024-04-25	The Board of Directors has established an Audit Committee currently consisting of Keith L. Brownlie, Chair, James J. Marino and Harry H. Penner, Jr. ... The Board of Directors has established a Compensation and Organization Development Committee currently consisting of James J. Marino, Chair, Cheryl L. Cohen and Harry H. Penner, Jr. ... The amounts in the Option Awards column reflect the grant date fair value in accordance with U.S. GAAP of stock option awards made in 2023 to each of our non-employee directors for awards pursuant to the 2021 Incentive Plan subject to a vesting schedule whereby an equal number of the shares of common stock shall become vested and no longer be subject to risk of forfeiture (so long as the director remains a member of the Board as of such date).